PIPELINE AND R&D
PIPELINE AND R&D
Working to Bring New Medicines to Patients to Address Immediate Unmet Needs
Arvinas is dedicated to advancing comprehensive programs in oncology and neurodegeneration, including against targets that have traditionally been deemed “undruggable.”
We Create PROteolysis TArgeting Chimeras
We are engineering an expansive pipeline of proteolysis targeting chimeras, or PROTACs, designed to harness the body’s own natural protein disposal system (the ubiquitin proteasome system) to selectively and efficiently degrade and remove disease-causing proteins.
Our Research
PROTAC degraders have clear characteristics that may provide potential advantages over other modalities in oncology and neurodegenerative diseases. Arvinas is the first targeted protein degradation company with an investigational drug to complete a pivotal trial and submit a New Drug Application to the U.S. Food and Drug Administration.
Oncology
Our pipeline of PROTACs in oncology have the potential ability to overcome evolving resistance mechanisms, target classically “undruggable” proteins, and offer oral therapies that could provide a new treatment option in areas of unmet needs.
Neurology
We are pioneering the discovery of PROTACs in historically difficult-to-treat neurologic diseases, with orally administered PROTACs that have demonstrated the ability to penetrate the blood-brain barrier in clinical studies. In preclinical studies, PROTACs also reached targets in deep-brain regions impacted in neurodegenerative diseases and in skeletal muscle, which could be relevant for neuromuscular disorders.
Pipeline
Discover more about our pipeline and clinical programs, including potential therapies for life-threatening cancers and devastating neurological disorders.
If you’re inspired, please take a look at the current list of opportunities to join our team.
- Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation. (Press Release, April 4, 2025).
- Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®. (Press Release, October 5, 2025).